HIP
JAZZ icon

Hatteras Investment Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Hatteras Investment Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-9,384
Closed -$1.62M – 123
2015
Q1 		$1.62M Buy
+9,384
New +$1.61M 0.87% 40

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Hatteras Investment Partners's JAZZ Position: Q2 2015 in Review

Hatteras Investment Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2015, closing a stake of 9,384 shares — an estimated $1.62M sold.

Hatteras Investment Partners first reported a position in JAZZ in Q1 2015 and held it in 1 quarter. The position peaked at $1.62M in Q1 2015. 373 funds tracked by Wall St. Rank hold JAZZ as of Q2 2015.

  • Hatteras Investment Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Hatteras Investment Partners sold 9,384 Jazz Pharmaceuticals shares in Q2 2015, an estimated $1.62M.
  • Hatteras Investment Partners first reported a position in Jazz Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Hatteras Investment Partners's Jazz Pharmaceuticals position peaked at $1.62M in Q1 2015.
  • 373 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2015.

Based on Hatteras Investment Partners's 13F filing for Q2 2015, filed 13 Aug 2015.